PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6668-6674

  Long, S Wesley ^a   Olsen, Randall J ^a   Mehta, Shrenik C ^b   Palzkill, Timothy ^b   Cernoch, Patricia L ^a   Perez, Katherine K ^a   Musick, William L ^a   Rosato, Adriana E ^a   Musser, James M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; LINEZOLID; MEROPENEM; MINOCYCLINE; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; CEPHALOSPORIN DERIVATIVE; PENICILLIN BINDING PROTEIN; PROTEIN MUTS;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENOME; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING SITE; BROTH DILUTION; CASE REPORT; CATHETER INFECTION; CHEMICAL ANALYSIS; CRYSTAL STRUCTURE; CYSTIC FIBROSIS; GENE SEQUENCE; GENETIC COMPLEMENTATION; HUMAN; IC50; MALE; MEDICAL HISTORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SPUTUM; YOUNG ADULT; COMPLICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NUCLEOTIDE SEQUENCE; STAPHYLOCOCCAL INFECTIONS;

ADULT; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; BINDING SITES; CEPHALOSPORINS; CYSTIC FIBROSIS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTS DNA MISMATCH-BINDING PROTEIN; PENICILLIN-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84908431770     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03622-14     Document Type: Article

References (35)

1. Bush K, Heep M, Macielag MJ, Noel GJ. 2007. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin. Investig. Drugs 16:419-429. http://dx.doi.org/10.1517/13543784.16.4.419.
2. Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Hamel A, Bugnon D, Ge JY, Potel G. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400. http://dx.doi.org/10.1128/AAC.01242-06.
3. Parish D, Scheinfeld N. 2008. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr. Opin. Investig. Drugs 9:201-209.
4. Sader HS, Fritsche TR, Jones RN. 2008. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1153-1155. http://dx.doi.org/10.1128/AAC.01351-07.
5. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Jones RN, Mendes RE, Sader HS. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J. Antimicrob. Chemother. 65(Suppl 4):S17-S31. http://dx.doi.org/10.1093/jac/dkq252.
7. Jones RN, Farrell DJ, Mendes RE, Sader HS. 2011. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J. Antimicrob. Chemother. 66(Suppl 3):S69-S80. http://dx.doi.org/10.1093/jac/dkr101.
8. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K. 2012. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J. Antimicrob. Chemother. 67:1321-1324. http://dx.doi.org/10.1093/jac/dks069.
9. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob. Agents Chemother. 56:2933-2940. http://dx.doi.org/10.1128/AAC.00330-12.
10. Smyth DS, McDougal LK, Gran FW, Manoharan A, Enright MC, Song JH, de Lencastre H, Robinson DA. 2010. Population structure of a hybrid clonal group of methicillin-resistant Staphylococcus aureus, ST239-MRSA-III. PLoS One 5:e8582. http://dx.doi.org/10.1371/journal.pone.0008582.
11. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita N, Gardete S, Tavares A, Day N, Lindsay JA, Edgeworth JD, de Lencastre H, Parkhill J, Peacock SJ, Bentley SD. 2010. Evolution of MRSA during hospital transmission and intercontinental spread. Science 327:469-474. http://dx.doi.org/10.1126/science.1182395.
12. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. 2014. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J. Antimicrob. Chemother. 69:2065-2075. http://dx.doi.org/10.1093/jac/dku114.
13. Monecke S, Coombs G, Shore AC, Coleman DC, Akpaka P, Borg M, Chow H, Ip M, Jatzwauk L, Jonas D, Kadlec K, Kearns A, Laurent F, O'Brien FG, Pearson J, Ruppelt A, Schwarz S, Scicluna E, Slickers P, Tan H-L, Weber S, Ehricht R. 2011. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus. PLoS One 6:e17936. http://dx.doi.org/10.1371/journal.pone.0017936.
14. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103:8487-8492. http://dx.doi.org/10.1073/pnas.0602138103.
15. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR. 2011. Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. PLoS One 6:e24301. http://dx.doi.org/10.1371/journal.pone.0024301.
16. Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18:821-829. http://dx.doi.org/10.1101/gr.074492.107.
17. Nusbaum C, Ohsumi TK, Gomez J, Aquadro J, Victor TC, Warren RM, Hung DT, Birren BW, Lander ES, Jaffe DB. 2009. Sensitive, specific polymorphism discovery in bacteria using massively parallel sequencing. Nat. Methods 6:67-69. http://dx.doi.org/10.1038/nmeth.1286.
18. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K. 2001. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:1225-1240. http://dx.doi.org/10.1016/S0140-6736(00)04403-2.
19. Huson DH, Bryant D. 2006. Application of phylogenetic networks in evolutionary studies. Mol. Biol. Evol. 23:254-267. http://dx.doi.org/10.1093/molbev/msj030.
20. Zhao G, Meier TI, Kahl SD, Gee KR, Blaszczak LC. 1999. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob. Agents Chemother. 43:1124-1128.
21. Finan JE, Rosato AE, Dickinson TM, Ko D, Archer GL. 2002. Conversion of oxacillin-resistant staphylococci from heterotypic to homotypic resistance expression. Antimicrob. Agents Chemother. 46:24-30. http://dx.doi.org/10.1128/AAC.46.1.24-30.2002.
22. Luong TT, Lee CY. 2006. The arl locus positively regulates Staphylococcus aureus type 5 capsule via an mgrA-dependent pathway. Microbiology 152:3123-3131. http://dx.doi.org/10.1099/mic.0.29177-0.
23. Lim D, Strynadka NCJ. 2002. Structural basis for the β lactam resistance of PBP 2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Mol. Biol. 9:870-876. http://dx.doi.org/10.1038/nsb858.
24. Grantham R. 1974. Amino acid difference formula to help explain protein evolution. Science 185:862-864. http://dx.doi.org/10.1126/science.185.4154.862.
25. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA. 2013. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc. Natl. Acad. Sci. U. S. A. 110:16808-16813. http://dx.doi.org/10.1073/pnas.1300118110.
26. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. 2008. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2089-2096. http://dx.doi.org/10.1128/AAC.01403-07.
27. Moisan H, Pruneau M, Malouin F. 2010. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716. http://dx.doi.org/10.1093/jac/dkp503.
28. Besier S, Zander J, Kahl BC, Kraiczy P, Brade V, Wichelhaus TA. 2008. The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 52:2183-2189. http://dx.doi.org/10.1128/AAC.01395-07.
29. Chatterjee I, Kriegeskorte A, Fischer A, Deiwick S, Theimann N, Proctor RA, Peters G, Herrmann M, Kahl BC. 2008. In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus. J. Bacteriol. 190:834-842. http://dx.doi.org/10.1128/JB.00912-07.
30. Lannergard J, von Eiff C, Sander G, Cordes T, Seggewiss J, Peters G, Proctor RA, Becker K, Hughes D. 2008. Identification of the genetic basis for clinical menadione-auxotrophic small-colony variant isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 52:4017-4022. http://dx.doi.org/10.1128/AAC.00668-08.
31. Sendi P, Proctor RA. 2009. Staphylococcus aureus as an intracellular pathogen: the role of small colony variants. Trends Microbiol. 17:54-58. http://dx.doi.org/10.1016/j.tim.2008.11.004.
32. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4:295-305. http://dx.doi.org/10.1038/nrmicro1384.
33. Zhang H, Xiao M, Yang Q-W, Wang Y, Wang H, Zhao Y, Brown M, Zhao H-R, Kong F, Xu Y-C. 2013. High ceftaroline non-susceptibility in Staphylococcus aureus isolated from acute skin infections in 15 tertiary hospitals in China. J. Med. Microbiol. 62:496-497. http://dx.doi.org/10.1099/jmm.0.052522-0.
34. Hudson LO, Reynolds C, Spratt BG, Enright MC, Quan V, Kim D, Hannah P, Mikhail L, Alexander R, Moore DF, Godoy D, Bishop CJ, Huang SS. 2013. Diversity of methicillin-resistant Staphylococcus aureus strains isolated from residents of 26 nursing homes in Orange County, California. J. Clin. Microbiol. 51:3788-3795. http://dx.doi.org/10.1128/JCM.01708-13.
35. Olsen RJ, Long SW, Musser JM. 2012. Bacterial genomics in infectious disease and the clinical pathology laboratory. Arch. Pathol. Lab. Med. 136:1414-1422. http://dx.doi.org/10.5858/arpa.2012-0025-RA.